The short answer
BPC-157's reported mechanism is described as multi-pathway: angiogenic signalling including VEGF-related effects, interactions with growth-factor systems, and effects on nitric oxide pathways. No receptor has been identified and no single defining molecular action has emerged.
Key facts
- Receptor
- None identified
- Reported pathways
- Angiogenic, growth-factor, nitric oxide
- Defining action
- None established
- Contrast
- TB-500 has one clear molecular function
- Evidence type
- Predominantly rodent models
- Consequence
- Mechanism is descriptive, not mapped
What multi-pathway actually signals
This phrasing needs careful reading. Multi-pathway can mean a compound acts at several points, or it can mean no single mechanism has been pinned down and the literature lists what has been observed. For BPC-157 the fair reading is closer to the second: effects are reported across several systems without a unifying molecular event connecting them.
The angiogenic thread
Seiwerth and colleagues reported on BPC-157 and blood vessels in Current Pharmaceutical Design in 2014, and vascular effects recur throughout the literature. Angiogenesis is a plausible common thread, because new vessel formation underlies repair in most of the tissues where effects have been reported (gut, tendon, ligament, muscle).
Research material referenced
BPC-157 5mg, third-party HPLC tested
The absence that shapes everything
No receptor has been identified. That is the same gap DSIP has, and it has the same consequence: without a molecular target there is no binding to measure, no dose-response to construct at the receptor level, no antagonist to design, and no way to test whether an observed effect runs through the proposed pathway. Mechanism can be described but not demonstrated.
The contrast with TB-500
TB-500's parent is the principal G-actin sequestering protein in many cell types, one clear, well-characterised molecular function from which downstream effects can be reasoned. BPC-157 has no equivalent anchor. It has more clinical development and a weaker mechanistic picture, which is an unusual combination.
Why breadth invites caution
A compound reported active in gastrointestinal, musculoskeletal, vascular and ocular models is either truly pleiotropic or is being tested by investigators with a strong prior. Compounds that appear to work in everything have a poor historical record, and that is a reason for the independent Phase 2 trial to matter more than further preclinical breadth.
What would resolve it
Identification of a molecular target, which would convert a list of observations into a mechanism. Failing that, a clinical result in a properly controlled trial would at least establish whether the effect is real, even without explaining it. NCT07437547 addresses the second question, not the first.
Frequently asked questions
Does BPC-157 have a receptor?
None has been identified. That is the central gap in its mechanistic picture.
What does multi-pathway mean here?
Effects reported across several systems without a unifying molecular event. It describes observations rather than a mapped mechanism.
How does this compare with TB-500?
TB-500's parent has one clear molecular function: actin sequestration. BPC-157 has more clinical development and a weaker mechanistic anchor.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al. Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al. Pharmaceuticals (Basel) 2023 (PMID 37513963)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- BPC-157 and Blood VesselsVascular effects recur across the BPC-157 literature and offer the most plausible common thread linking its reported activity in different tissues.
- Tendon and Ligament ModelsKrivic on Achilles detachment and Cerovecki on ligament healing, both in the Journal of Orthopaedic Research. What rat models can and cannot establish.
- Growth Factor Signalling in the BPC-157 LiteratureReported interactions with growth-factor systems are part of the multi-pathway description. What that means when no receptor for the peptide is known.
- BPC-157 Studied Effects, Sorted by EvidenceGastrointestinal, tendon, ligament and vascular models, plus clinical development as PL-14736 and a Phase 2 recruiting now. Ranked by how well established.
- BPC-157 Side Effects and the Absence of Human DataNo controlled human safety study exists. What the rodent literature reports, the theoretical concern that follows from its own mechanism, and what nobody knows.